摘要
目的探讨雷贝拉唑联合康复新液治疗幽门螺杆菌阴性胃溃疡的应用效果。方法纳入2016年6月至2017年6月我院90例幽门螺杆菌阴性胃溃疡患者,随机将其分为对照组与观察组,各45例。对照组给予单一雷贝拉唑治疗,观察组则给予雷贝拉唑联合康复新液治疗。比较两组治疗效果、胃溃疡愈合时间、症状消失时间、干预前、后患者炎症因子水平、药物不良反发生率。结果观察组患者的治疗总有效率为95.56%,高于对照组的68.89%(P<0.05);观察组患者的胃溃疡平均愈合时间、症状消失时间均短于对照组(P<0.05)。干预后,两组白细胞介素-6、C反应蛋白、肿瘤坏死因子-α均低于干预前,且观察组低于对照组(P<0.05)。两组患者的不良反应总发生率比较,差异不显著(P>0.05)。结论雷贝拉唑联合康复新液治疗幽门螺杆菌阴性胃溃疡的应用效果确切,可有效改善临床症状,缩短疗程,降低炎症因子水平,安全有效,值得推广应用。
Objective To investigate the effect of rabeprazole combined with Kangfuxin solution in the treatment of Helicobacter pylori negative gastric ulcer. Methods From June 2016 to June 2017, 90 patients with Helicobacter pylori negative gastric ulcer in our hospital were randomly divided into control group and observation group, with 45 cases in each group. The control group was treated with single rabeprazole. The observation group was treated with rabeprazole combined with Kangfuxin solution. The treatment effects, average healing time of gastric ulcer, time of symptom disappearance, and levels of inflammatory indexes before and after intervention and drug adverse reactions were compared between the two groups. Results The total effective rate of treatment in the observation group was 95.56%, which was higher than 68.89% in the control group(P〈0.05). The healing time of gastric ulcer and time of symptom disappearance in the observation group were shorter than those in the control group(P〈0.05). After intervention, the levels of interleukin-6, C-reactive protein and tumor necrosis factor-α in the two groups decreased, and those in the observation group were lower than the control group(P〈0.05). The difference in total incidence of complications in the two groups were not significant(P〉0.05). Conclusion Rabeprazole combined with Kangfuxin solution is effective in the treatment of Helicobacter pylori negative gastric ulcer,and it can effectively improve the clinical symptoms, shorten the course of treatment, reduce the levels of inflammatory indexed, which is safe and effective and worth popularizing.
作者
郭伦锋
尹志国
封卫毅
GUO Lun-feng;YIN Zhi-guo;FENG Wei-yi(Pharmacy Department, the First Affiliated Hospital of Medical College of Xi'an Jiaotong University, Xi'an 710061;Medicine Department, Ankang Central Hospital, Ankang 725000;Pharmacy Department,Ankang Central Hospital, Ankang 725000, China)
出处
《临床医学研究与实践》
2018年第14期98-99,共2页
Clinical Research and Practice
关键词
雷贝拉唑
康复新液
幽门螺杆菌阴性胃溃疡
rabeprazole
Kangfuxin solution
Helicobacter pylori negative gastric ulcer